title: New agents: great expectations not realized.
abstract: A number of new agents in acute myeloid leukemia (AML) have held much promise in recent years, but most have failed to change the therapeutic landscape. Indeed, with the exception of gemtuzumab ozogamicin (which was subsequently voluntarily withdrawn from the commercial market), no new agent has been approved for acute myeloid leukemia (AML) beyond the 7 + 3 regimen, which was has been in use for over 40 years. This review touches upon the potential reasons for these failures and explores the newer therapeutic approaches being pursued in AML.
authors.affiliation: Oncologic Sciences, University of South Florida, Tampa, USA; Department of Malignant Hematology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. Electronic address: Jeffrey.lancet@moffitt.org.
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Lancet
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000627:therapeutic use; D052160:Benzothiazoles / Q000627:therapeutic use; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000079982:Gemtuzumab; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D009287:Naphthyridines / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012074:Remission Induction; D019311:Staurosporine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016019:Survival Analysis; D013844:Thiazoles / Q000627:therapeutic use; D017211:Treatment Failure; D000077337:Vorinostat
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D052160:Benzothiazoles; D006877:Hydroxamic Acids; D009287:Naphthyridines; D010671:Phenylurea Compounds; D013844:Thiazoles; D000077337:Vorinostat; C544967:quizartinib; D003596:Cytosine; D000079982:Gemtuzumab; D019311:Staurosporine; C059539:midostaurin; C485113:vosaroxin; C117959:sapacitabine
keywords: AC220; CPX-351; FLAM; FLT3 inhibitor; acute myeloid leukemia, AML; clofarabine; flavopiridol; gemtuzumab; laromustine; lestaurtinib; lintuzumab; midostaurin; quizartinib; sapacitabine; tipifarnib